Welcome to LookChem.com Sign In|Join Free
  • or
3-Bromo-4(H)-thieno[3,2-b]pyrrole-5-carboxylic acid is a chemical compound that belongs to the class of organic compounds known as pyrroles and thiophenes. It features a five-membered unsaturated ring with four carbon atoms and one nitrogen atom in the case of pyrrole, and a thiophene ring, which is a five-membered aromatic ring composed of four carbon atoms and one sulfur atom. 3-BROMO-4(H)-THIENO[3,2-B]PYRROLE-5-CARBOXYLICACID's specific molecular structure determines its properties, such as molecular weight, boiling and melting points, and solubility.

332099-36-2

Post Buying Request

332099-36-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

332099-36-2 Usage

Uses

Used in Chemical Research:
3-BROMO-4(H)-THIENO[3,2-B]PYRROLE-5-CARBOXYLICACID is used as a research compound for exploring its chemical properties and potential applications in various fields.
Used as a Synthesis Intermediate:
3-BROMO-4(H)-THIENO[3,2-B]PYRROLE-5-CARBOXYLICACID is used as an intermediate in the synthesis of more complex chemicals, contributing to the development of new compounds with diverse applications.

Check Digit Verification of cas no

The CAS Registry Mumber 332099-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,2,0,9 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 332099-36:
(8*3)+(7*3)+(6*2)+(5*0)+(4*9)+(3*9)+(2*3)+(1*6)=132
132 % 10 = 2
So 332099-36-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H4BrNO2S/c8-3-2-12-5-1-4(7(10)11)9-6(3)5/h1-2,9H,(H,10,11)

332099-36-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-Bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid

1.2 Other means of identification

Product number -
Other names 3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:332099-36-2 SDS

332099-36-2Relevant academic research and scientific papers

Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues

Parmentier, Jean-Gilles,Portevin, Bernard,Golsteyn, Roy M.,Pierré, Alain,Hickman, John,Gloanec, Philippe,De Nanteuil, Guillaume

scheme or table, p. 841 - 844 (2009/08/07)

A series of thieno[3,2-b]pyrroloazepinones derivatives related to Hymenialdisine were prepared and tested for CHK1 inhibitory activity. Nanomolar inhibitions were achieved when electron-withdrawing substituents were introduced at position 3 of the thiophene ring.

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

-

Page/Page column 48, (2008/06/13)

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

USE OF FUSED PYRROLE CARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES AS D-AMINO ACID OXIDASE INHIBITORS

-

Page/Page column 18, (2008/06/13)

The present invention provides the use of fused pyrrole carboxylic acids of formula (I) for the manufacture of a medicament to inhibit D-amino acid oxidase, particularly for the treatment of neurodegenerative and psychiatric disorders or diseases; certain

Use of glycogen phosphorylase inhibitors

-

, (2008/06/13)

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

-

, (2008/06/13)

This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compou

Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

-

, (2008/06/13)

This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compou

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 332099-36-2